<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01865812</url>
  </required_header>
  <id_info>
    <org_study_id>747-205</org_study_id>
    <nct_id>NCT01865812</nct_id>
  </id_info>
  <brief_title>Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis</brief_title>
  <official_title>A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if obeticholic acid (OCA) has an effect on
      cholesterol levels in the blood in patients with PBC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline in High-density lipoprotein (HDL) Metabolism</measure>
    <time_frame>Week 4, Week 8 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>HDL metabolism will be assessed by measuring HDL cholesterol concentration, HDL particle size and number.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Lipoprotein Metabolism</measure>
    <time_frame>Week 4, Week 8 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lipoprotein metabolism will be assessed by measuring the following:
concentrations of total cholesterol and triglycerides
Low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol concentrations, particle size and number
concentrations of apolipoprotein A (ApoA), apolipoprotein B (ApoB), apolipoprotein E (ApoE), and lipoprotein (a) [Lp(a)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Reverse Cholesterol Transport</measure>
    <time_frame>Week 4, Week 8 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Components of reverse cholesterol transport will also be assessed as part of the lipoprotein analysis. This will include measurements of:
HDL capacity to accept cholesterol measured by lecithin-cholesterol acyltransferase (LCAT) and Cholesterol ester transfer protein (CETP) activity.
pre-β1 HDL concentration
macrophage cholesterol efflux</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of OCA and OCA conjugates</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>In a subset of patients who agree to participate, non-compartmental pharmacokinetic parameters of OCA and its conjugates (glyco-OCA and tauro-OCA) will be assessed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fasting levels of OCA and Conjugates</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in fibroblast growth factor 19 (FGF-19)</measure>
    <time_frame>Week 4, Week 8 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Lipoprotein X</measure>
    <time_frame>Week 4, Week 8 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Markers of inflammation including: C-Reactive Protein, GlycA and GlycB</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>OCA: 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>obeticholic acid, oral administration, 10mg, 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>obeticholic acid (OCA)</intervention_name>
    <description>All subjects will be treated with OCA (oral administration, 10 mg, once daily) for 8 weeks and should continue their prestudy dose of ursodeoxycholic acid (UDCA).</description>
    <arm_group_label>OCA: 10 mg</arm_group_label>
    <other_name>6α-ethyl chenodeoxycholic acid (6-ECDCA); INT-747</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Definite or probable primary biliary cirrhosis (PBC) diagnosis as demonstrated by the
             presence of ≥ 2 of the following 3 diagnostic factors:

               -  History of elevated alkaline phosphatase (ALP) levels for at least 6 months

               -  A positive anti-microbial antibody (AMA) titer or, if AMA negative or in low
                  titer (&lt;1:80), PBC specific antibodies

               -  Liver biopsy consistent with PBC

          2. Age ≥ 18 years

          3. Taking UDCA for at least 12 months (stable dose for ≥ 3 months) prior to Day 0 or
             unable to tolerate UDCA (no UDCA for ≥ 3 months prior to Day 0)

          4. Contraception:  Female subjects must be postmenopausal, surgically sterile, or if
             premenopausal, be prepared to use ≥ 1 effective (≤ 1% failure rate) method of
             contraception during the trial and until at least 30 days after the last dose of
             Investigational Product.

          5. Must provide written informed consent and agree to comply with the trial protocol.

        Exclusion Criteria:

          1. Subjects with decompensated PBC (as determined by the Investigator)

          2. Severe pruritus or systemic treatment for pruritus (e.g. treatment with bile acid
             sequestrants or rifampicin) within 2 months of Day 0

          3. History or presence of other significant liver diseases including:

               -  Active or chronic Hepatitis B or C virus (HBV, HCV) infection

               -  Primary sclerosing cholangitis (PSC)

               -  Alcoholic liver disease

               -  Definite autoimmune liver disease or overlap hepatitis

               -  Nonalcoholic steatohepatitis (NASH)

             NOTE: Subjects with Gilbert's disease or those with a history of hepatitis B who are
             currently antigen negative and seroconverted should not be considered exclusionary

          4. Uncontrolled diabetes or other uncontrolled or unstable medical condition that may
             interfere with trial results

          5. Administration of any of the following medications as specified below:

               -  Prohibited 28 days prior to Day 0: bile acid sequestrants (BAS) including
                  cholestyramine, colesevelam, or colestipol

               -  Prohibited 3 months prior to Day 0 and throughout trial participation:
                  serum-lipid modifying agents including 3-hydroxy-3-methylglutaryl-coenzyme A
                  (HMG CoA) reductase inhibitors, fenofibrate or other fibrates, nicotinic acid
                  and derivatives, ezetimibe, Vitamin E (other than as standard dietary
                  supplement), omega-3 fatty acid containing dietary supplements

               -  Prohibited 6 months prior to Day 0 and throughout the trial participation:
                  azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil,
                  pentoxifylline; budesonide and other systemic corticosteroids; potentially
                  hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazide, or
                  nitrofurantoin)

               -  Prohibited 12 months prior to Day 0 and throughout the trial participation:
                  antibodies or immunotherapy directed against interleukins or other cytokines or
                  chemokines

          6. Planned change in diet or exercise habits during participation in the trial

          7. Presence or history of clinically significant cardiac arrhythmias that may prohibit
             the subject from participating in the trial

          8. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a
             positive serum pregnancy test), or lactating

          9. Recent (3 months prior to day 0) participation in another trial involving OCA or
             participation in another investigational trial (30 days prior to Day 0) and during
             the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Shapiro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Intercept Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathi I. Sciacca</last_name>
    <phone>858-652-6803</phone>
    <email>csciacca@interceptpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberly Fowler</last_name>
    <phone>858-964-1573</phone>
    <email>kfowler@interceptpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Carvalho</last_name>
      <phone>305-243-4639</phone>
      <email>scarvalho@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Keach</last_name>
      <phone>507-538-0678</phone>
      <email>keach.jill@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jayant Talwalkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duyang Kim, MPH</last_name>
      <phone>212-844-6446</phone>
      <email>dukim@chpnet.org</email>
    </contact>
    <investigator>
      <last_name>Henry C. Bodenheimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Williams</last_name>
      <phone>804-675-6848</phone>
      <email>kimberly.williams1@va.gov</email>
    </contact>
    <investigator>
      <last_name>Velimir A. Luketic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anhaita Jamula</last_name>
      <phone>206-341-1978</phone>
      <email>anhaita.jamula@vmmc.org</email>
    </contact>
    <investigator>
      <last_name>Kris Kowdley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
